SS-31 (Elamipretide) vs MOTS-c: The Mitochondria Face-Off

Somewhere inside almost every cell in your body, two entirely different molecular strategies are being studied against the same target: the mitochondrion. One is a synthetic tetrapeptide that clings to a lipid most people have never heard of and refuses to let it fall apart. The other is a message your own mitochondrial DNA has been quietly sending for millions of years — researchers only learned to read it in 2015. SS-31 (elamipretide) and MOTS-c could not approach mitochondrial biology more differently, yet they keep turning up in the same conversation about cellular energy, ageing research, and what comes next for the field.

Both compounds are sold by Crown Peptides strictly for laboratory research use, not for human consumption, and neither is approved as a treatment for any condition discussed in this guide unless specifically noted otherwise below.

• SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that binds cardiolipin to stabilise the inner mitochondrial membrane, while MOTS-c is a 16-amino-acid peptide encoded directly in mitochondrial DNA that activates AMPK and behaves like an exercise mimetic in preclinical models.
• Elamipretide has the deeper clinical trial record of the two: it holds FDA accelerated approval, under the brand name Forzinity, specifically for Barth syndrome, built on the TAZPOWER trial — though its Phase 3 trial in primary mitochondrial myopathy (MMPOWER-3) and its Phase 2 dry AMD trial (ReCLAIM-2) both missed their stated primary endpoints.
• MOTS-c’s evidence base is still mostly preclinical and cell-based, rooted in the 2015 discovery by Changhan Lee, Pinchas Cohen and colleagues at USC — though a Phase 2a human trial testing MOTS-c in prediabetes and insulin sensitivity is now enrolling.
• The two peptides approach mitochondrial health from opposite directions: one physically reinforces the organelle’s membrane architecture, the other reprograms nuclear gene expression from inside the cell in response to metabolic stress.
• Crown Peptides supplies both compounds with a batch-specific Certificate of Analysis, HPLC purity verification, and mass-spectrometry identity confirmation.

Two Signals, One Organelle

Mitochondria research has quietly become one of the most active corners of peptide science, and it’s not hard to see why. Every tissue that burns a lot of energy — heart, skeletal muscle, retina, brain — lives or dies by how well its mitochondria hold up. When the inner mitochondrial membrane loses structural integrity, or when the signalling network that tells a cell to build new mitochondria goes quiet, the downstream effects show up everywhere from muscle fatigue to metabolic dysfunction. That’s the shared territory SS-31 and MOTS-c occupy, even though they were discovered a world apart, by different labs, working from completely different starting assumptions.

SS-31 began as a chemistry problem: could a small, stable peptide be engineered to find its way specifically to the inner mitochondrial membrane and stay there? MOTS-c began as a genomics surprise: mitochondrial DNA, long assumed to only encode components of the electron transport chain, turned out to be hiding an entire peptide-coding open reading frame inside its 12S ribosomal RNA gene. One compound was built. The other was found. That distinction shapes everything about how each one is studied today, and it’s the thread running through this whole comparison.

The Guardian at the Membrane

Elamipretide’s structure is almost deceptively simple: four amino acids — D-arginine, 2,6-dimethyltyrosine (Dmt), lysine, and phenylalanine, capped with an amide — arranged so that two residues carry a positive charge and two are aromatic. That alternating pattern is the entire trick. The positive charges create electrostatic attraction toward cardiolipin, a phospholipid found almost exclusively on the inner mitochondrial membrane and, critically, nowhere else in meaningful concentration. The aromatic rings on Dmt and phenylalanine shield those charges just enough to let the peptide cross lipid membranes freely, so instead of being trapped outside the cell by its own charge, SS-31 moves through the cytosol, threads the outer mitochondrial membrane, and concentrates precisely where cardiolipin lives (a 2025 structural and mechanistic review in International Journal of Molecular Sciences lays out this aromatic-cationic targeting mechanism in detail).

Once there, the peptide’s job is essentially architectural. Cardiolipin isn’t just another membrane lipid — it’s the molecule that gives the inner mitochondrial membrane its characteristic folded cristae structure and helps organise the protein complexes of the electron transport chain into efficient super-complexes. When cardiolipin gets oxidised or loses its normal conformation, cristae flatten, electron transport becomes leaky, and that leakage is a major source of the reactive oxygen species that drive oxidative stress. By binding cardiolipin and stabilising its structure, SS-31 research has repeatedly shown reduced electron leakage, better-preserved cristae architecture, and improved ATP output in stressed mitochondria — the mechanism that gave the compound its original working name, “mitochondria-targeted antioxidant,” even though its effect is really upstream of antioxidant activity: it prevents the leak rather than mopping up the damage afterward.

This is also why SS-31 shows up so often in research on tissues that are unusually cardiolipin-dependent, cardiac and skeletal muscle chief among them. A 2024 study published in Scientific Reports examined SS-31 treatment in a mouse model of Barth syndrome — a genetic disorder caused by mutations in the tafazzin gene that leave cardiolipin permanently malformed — and found the peptide improved cardiac mitochondrial morphology and corrected defective mitophagy, the cellular process that clears out damaged mitochondria. That’s a tidy illustration of why cardiolipin-binding peptides are interesting to researchers well beyond any single disease: cardiolipin dysfunction is a downstream feature of an enormous range of stress and ageing-related conditions, not just one rare genetic disorder.

If you want to go deeper on the mechanism, Crown Peptides’ full SS-31 peptide guide walks through the cristae-stabilisation research in more detail, alongside dosing formats researchers commonly use.

From Bench to Barth Syndrome: Elamipretide’s Trial Record

Here’s where elamipretide separates itself from almost every other compound in the mitochondrial research space: it has actually been through the full clinical trial gauntlet, in multiple disease populations, and the results are a genuinely mixed and genuinely interesting story — not a straight line to success, but not a dead end either.

Start with the win. Elamipretide’s longest and most consequential clinical programme ran in Barth syndrome, an ultra-rare X-linked genetic disorder in which a defective tafazzin enzyme leaves cardiolipin structurally abnormal, producing cardiomyopathy and profound skeletal muscle weakness from childhood. The TAZPOWER trial (NCT03098797), a randomised, double-blind, placebo-controlled Phase 2 study, tested subcutaneous elamipretide in Barth syndrome patients and tracked them through an extended 168-week open-label follow-up, measuring outcomes like knee extensor muscle strength and the six-minute walk test. The data were compelling enough that in September 2025 the FDA granted elamipretide — marketed as Forzinity — accelerated approval as the first-ever approved treatment for Barth syndrome, specifically for patients weighing at least 30 kg, based on improvement in knee extensor muscle strength as an intermediate clinical endpoint. It’s worth being precise about what that approval actually covers: it’s a single-indication accelerated approval for a specific rare genetic disease in the US market, delivered as a prescription pharmaceutical product, not a general green light for elamipretide as a compound. Crown Peptides’ SS-31 is supplied strictly as a research material, distinct from that approved drug formulation, but the approval itself is a genuinely significant data point — it’s rare for any mitochondria-targeted peptide to clear that bar, and it validates the cardiolipin-stabilisation mechanism in living human patients, not just cell culture.

Elsewhere, the picture is more complicated, and worth reporting honestly rather than glossing over. The Phase 3 MMPOWER-3 trial tested elamipretide in a broader population of 218 patients with primary mitochondrial myopathy, a condition distinct from Barth syndrome, over 24 weeks. It did not meet its co-primary endpoints — there was no statistically significant difference from placebo on the six-minute walk test or on a patient-reported fatigue score, according to results published in Neurology. But a post hoc subgroup analysis turned up something genuinely worth watching: patients whose mitochondrial myopathy stemmed from nuclear DNA mutations, rather than mitochondrial DNA mutations, showed a 25.2-metre improvement advantage on the walk test compared with placebo — a signal the study authors themselves described as “encouraging and hypothesis-generating.” It’s a textbook example of why a missed primary endpoint in a genetically heterogeneous trial population doesn’t necessarily mean the mechanism failed; it can mean the trial pooled together patients who were never going to respond the same way, and future research needs to stratify by genotype from the start.

A similar pattern shows up in elamipretide’s ophthalmology programme. The Phase 2 ReCLAIM-2 trial tested subcutaneous elamipretide in patients with dry age-related macular degeneration and geographic atrophy, and its co-primary endpoints — change in low-luminance visual acuity and geographic atrophy lesion growth — were not met. Reported honestly, that’s a miss. But a secondary measure lit up: elamipretide-treated patients showed a 43% reduction in ellipsoid zone attenuation at 48 weeks, a structural marker of photoreceptor and mitochondrial health in the retina, alongside a statistically significant categorical improvement in visual acuity for a subset of patients. That signal was strong enough that Stealth BioTherapeutics moved the programme into Phase 3 trials — ReNEW and ReGAIN — now using photoreceptor preservation as the primary outcome measure instead. Trials like this are exactly why elamipretide keeps attracting research interest even where the headline result disappoints: the mechanism keeps producing real, measurable biological effects, even when the specific clinical endpoint chosen for a given trial doesn’t land.

Taken together, elamipretide’s record reads less like a single success or failure story and more like a compound whose core mechanism — cardiolipin stabilisation — keeps generating consistent structural and functional signals across completely unrelated tissues: cardiac and skeletal muscle in Barth syndrome, skeletal muscle again in mitochondrial myopathy, and retinal photoreceptors in macular degeneration. That kind of cross-tissue consistency is unusual, and it’s a big part of why the compound remains one of the most closely watched mitochondria-targeted peptides in active research.

The Messenger Hiding Inside Your Mitochondrial DNA

MOTS-c has one of the better discovery stories in modern peptide science, mostly because nobody was looking for it. For decades, the standard model of mitochondrial DNA held that its 37 genes encoded only components of the electron transport chain and the machinery to translate them — full stop. Then, in 2015, a research team led by Changhan Lee working in Pinchas Cohen’s laboratory at the USC Leonard Davis School of Gerontology, alongside longevity researcher Kelvin Yen, identified a previously unrecognised open reading frame inside the mitochondrial 12S rRNA gene. It encoded a 16-amino-acid peptide they named MOTS-c — “mitochondrial open reading frame of the twelve S rRNA type-c.” It was, in effect, a message hiding in plain sight inside a gene everyone assumed had already given up all its secrets.

That discovery, published in Cell Metabolism in 2015, didn’t just report a new peptide — it reported one that actively did something. In the founding study, MOTS-c administration in mice prevented diet-induced obesity and insulin resistance, and enhanced skeletal muscle glucose uptake independent of insulin signalling. That last detail mattered enormously to metabolic researchers, because it suggested a pathway to improving glucose handling that didn’t route through the insulin receptor at all — a genuinely novel angle in a field where most therapeutic strategies converge on the same handful of targets.

Since then, the MOTS-c story has kept getting more interesting rather than less. A 2018 follow-up study in Cell Metabolism found that under metabolic stress, MOTS-c doesn’t just act locally at the mitochondrion — it translocates into the nucleus and directly regulates nuclear gene expression, including antioxidant response pathways. That’s a remarkable finding on its own terms: a peptide encoded by mitochondrial DNA travelling to the nucleus to influence the expression of genes encoded by an entirely separate genome. It reframes MOTS-c not simply as a “mitochondrial peptide” in the narrow sense, but as a genuine inter-organelle signalling molecule — a messenger coordinating the conversation between the cell’s two genomes in real time as conditions change. For a deeper dive into that signalling mechanism and how it compares with other longevity-adjacent compounds, Crown Peptides’ NAD+ vs MOTS-c comparison is worth a read.

How MOTS-c Talks to Your Cells

Mechanistically, MOTS-c’s headline pathway runs through AMPK — AMP-activated protein kinase, the cell’s master energy sensor. Research indicates MOTS-c increases intracellular levels of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an intermediate in purine biosynthesis that happens to be a potent natural AMPK activator. Elevated AICAR switches AMPK on, and AMPK activation is the same signalling event that occurs during genuine physical exercise, when a muscle cell’s ATP-to-AMP ratio shifts and the cell responds by ramping up glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. That overlap is exactly why MOTS-c earned its reputation as an “exercise mimetic” peptide in the research literature — it appears to trip the same metabolic switch that a hard training session trips, without requiring the training session itself.

The downstream effects researchers have documented from that AMPK activation read like a checklist of metabolic research priorities: enhanced skeletal muscle glucose uptake, increased fatty acid oxidation, greater energy expenditure, and resistance to diet-induced obesity in animal models. More recent work has pushed the compound’s research relevance even further. Studies have connected MOTS-c to pancreatic islet cell senescence, with data suggesting the peptide may help delay the cellular ageing processes that contribute to diabetes progression, and separate research has examined its role in plasma membrane repair through facilitating TRIM72 translocation to the membrane — a completely different cellular process from glucose metabolism, and a sign of just how broadly this small peptide’s influence appears to extend once researchers started looking for it.

There’s also a genuinely interesting observational thread in human research: circulating MOTS-c levels decline measurably with age, and studies in cancer survivors have found that structured aerobic and resistance exercise programmes raise circulating MOTS-c levels in a dose-responsive way. None of that is interventional evidence that administering the peptide replicates exercise in humans — it’s correlational and observational — but it’s a striking pattern that keeps this compound firmly in the sights of ageing and exercise-metabolism researchers. Anecdotally, some research communities discussing MOTS-c self-report subjective changes in energy and training capacity during self-directed research — reports like that are worth mentioning because they’re part of the broader conversation around the compound, but they’re anecdotal, not data, and they don’t substitute for controlled trial results. These informal reports are not research data, and Crown Peptides does not condone personal or human use of research compounds.

Crown Peptides’ MOTS-c peptide guide goes further into the AMPK/AICAR pathway and the specific animal-model studies behind it, for researchers who want the full mechanistic picture before designing a study.

Where the Human Data Actually Stands

It’s important to be precise here, because MOTS-c gets discussed online with a confidence level its current evidence base doesn’t quite support yet. The overwhelming majority of MOTS-c research to date is preclinical: rodent models, cell culture, and a smaller body of human observational data tracking naturally circulating MOTS-c levels against age, disease state, and exercise habits. That is not a knock on the compound — preclinical mechanistic research is exactly how every successful peptide therapeutic starts, and MOTS-c’s preclinical dataset is unusually deep and consistent for a peptide discovered only a decade ago.

But there is real, current movement toward interventional human research. A Phase 2a trial, registered as NCT07505745 and sponsored by Hudson Biotech, is now enrolling roughly 120 adults with prediabetes and excess weight to test whether twelve weeks of subcutaneous MOTS-c improves insulin sensitivity compared with placebo, alongside standardised lifestyle guidance. That’s a meaningful milestone — it’s the first randomised human interventional trial built specifically to test the metabolic hypothesis that came out of the original 2015 mouse data. It hasn’t reported results yet, so there’s nothing to overstate here either way, but its existence is itself the clearest sign yet that MOTS-c is moving from “interesting mitochondrial biology” toward a genuine clinical research pathway, following roughly the same trajectory elamipretide walked a decade earlier.

Two Different Strategies, One Shared Goal

Put side by side, SS-31 and MOTS-c make an unusually clean case study in how differently “mitochondrial peptide” research can actually work. SS-31 is fundamentally structural — it’s a membrane-stabilising molecule that goes exactly where cardiolipin lives and keeps the physical architecture of the electron transport chain intact under stress. Its research applications cluster around conditions where mitochondrial membrane integrity is the acute problem: cardiac stress, skeletal muscle fatigue, retinal photoreceptor loss, ischemia-reperfusion injury. MOTS-c is fundamentally regulatory — it’s a signalling molecule that reports metabolic stress status to both the cytoplasm and the nucleus, and its research applications cluster around systemic metabolic questions: insulin sensitivity, fat oxidation, exercise physiology, cellular senescence.

That’s not a competition with a single winner; it’s two different levers on the same machine. A researcher studying acute mitochondrial membrane damage — in a cardiac ischemia model, say — has very different needs from a researcher studying chronic metabolic dysregulation in a diet-induced obesity model, even though both projects would reasonably describe themselves as “mitochondrial research.” It’s also worth noting the compounds sit at very different points on the evidence timeline: elamipretide has an actual FDA-approved drug product behind it for one specific rare disease, plus a stack of Phase 2 and Phase 3 human trial data across three separate conditions. MOTS-c has a decade of consistent, expanding preclinical data and one enrolling Phase 2a human trial. Neither status is a reason to think less of either compound — they simply reflect how long each mechanism has been in active clinical development, and MOTS-c’s trajectory over the next several years is one of the more interesting things to watch in this space.

Researchers who want to examine both mechanisms side by side can find full specification and sourcing details on the SS-31 product page and the MOTS-c product page.

Why Purity Isn’t Negotiable With Either of These Peptides

Mitochondria-targeted research compounds are unusually unforgiving of sloppy synthesis, and SS-31 and MOTS-c illustrate that from two different angles. SS-31’s entire mechanism depends on a precise charge distribution across just four residues — the D-arginine and lysine positive charges, shielded exactly right by the Dmt and phenylalanine aromatic rings. A synthesis run with even minor truncation products, incomplete amidation, or racemisation at the chiral centres doesn’t just reduce potency — it can change how the molecule partitions between membranes altogether, which makes impurity profiling a genuine scientific necessity for this compound, not a formality. MOTS-c presents the opposite challenge: at 16 residues and a molecular weight above 2,100 daltons, it’s a considerably longer synthesis with more coupling steps, more opportunity for deletion sequences, and more surface area for oxidation-sensitive residues like methionine and tryptophan to degrade during storage or shipping.

That’s precisely why Crown Peptides tests every batch of both compounds rather than relying on a single validated process run. Each batch ships with its own Certificate of Analysis, generated from that specific production lot rather than a generic reference document. HPLC purity testing confirms the peptide content meets stated purity thresholds and flags truncation or deletion byproducts before they reach a researcher’s bench. Mass spectrometry identity confirmation independently verifies that the molecule in the vial matches the expected molecular weight and formula — for SS-31, confirming that 639.79 g/mol signature; for MOTS-c, confirming the considerably larger 2174.62 g/mol signature — catching any synthesis error that slipped past purity testing alone. Proper cold-chain storage and handling guidance matters just as much on the back end: both peptides are susceptible to degradation from freeze-thaw cycling and prolonged exposure to ambient temperature, and MOTS-c’s oxidation-prone residues make consistent cold storage even more important for maintaining research-grade integrity between the point of manufacture and the point of use. None of that is boilerplate — it’s the specific reason a research peptide supplier’s quality process matters more for compounds like these than for simpler, more chemically stable peptides.

The Road Ahead

Mitochondrial peptide research isn’t slowing down — if anything, the last two years have shown it accelerating on both fronts covered here. Elamipretide now has a genuine regulatory approval behind it, two Phase 3 programmes still generating data in AMD and mitochondrial myopathy, and a post hoc genotype signal that’s actively reshaping how future trials in genetically heterogeneous mitochondrial diseases get designed. MOTS-c has moved from a decade of tightly consistent preclinical findings into its first purpose-built human interventional trial, with a research community that keeps finding new downstream pathways — from islet cell senescence to membrane repair — every time it looks closer. Neither story is finished, and that’s exactly what makes this such an active area to be researching right now rather than a settled one.

For researchers building out a mitochondrial biology programme, the practical case for stocking both compounds is straightforward: they let you probe the organelle from its structural side and its signalling side without switching suppliers or compromising on verified purity. Explore the full documentation, batch data, and ordering details on the SS-31 (elamipretide) product page and the MOTS-c product page, or start from the Crown Peptides homepage to browse the wider mitochondrial research catalogue.

Frequently Asked Questions

Is SS-31 the same thing as elamipretide?

Yes — SS-31 is the original research designation, and elamipretide is the compound’s international nonproprietary name (INN). They refer to the identical tetrapeptide sequence, D-Arg-Dmt-Lys-Phe-NH2. You’ll also see it referenced by earlier development codes like MTP-131 in some older literature, all describing the same molecule.

Has elamipretide been approved by any regulator?

The FDA granted elamipretide accelerated approval in the United States under the brand name Forzinity in September 2025, specifically for Barth syndrome in patients weighing at least 30 kg, based on the TAZPOWER trial data. That approval is narrow by design — it covers one specific rare genetic disease as a prescription pharmaceutical product — and doesn’t extend to other conditions elamipretide has been studied for, such as primary mitochondrial myopathy or dry AMD, where trials are still ongoing.

Does MOTS-c have any human clinical trial data yet?

An interventional human trial is now enrolling — a Phase 2a study (NCT07505745) testing MOTS-c’s effect on insulin sensitivity in adults with prediabetes and excess weight. Results aren’t available yet. Prior to this, MOTS-c’s evidence base has consisted of preclinical animal and cell studies plus human observational data on naturally circulating MOTS-c levels.

Why do SS-31 and MOTS-c get compared so often?

Because they’re two of the most mechanistically distinct approaches to the same organelle. SS-31 physically reinforces the mitochondrial membrane by binding cardiolipin; MOTS-c acts as a mobile signal that reports metabolic status to the cell’s AMPK pathway and, under stress, to the nucleus itself. Researchers studying mitochondrial biology broadly often want both angles covered, which is why the two compounds keep appearing side by side in the same research conversations.